Braga E A, Loginov V I, Filippova E A, Burdennyi A M, Pronina I V, Kazubskaya T P, Khodyrev D S, Utkin D O, Kushlinskii D N, Adamyan L V, Kuslinskii N E
Research Institute of General Pathology and Pathophysiology, Moscow, Russia.
Research Center of medical Genetics, Moscow, Russia.
Bull Exp Biol Med. 2018 Dec;166(2):253-256. doi: 10.1007/s10517-018-4326-0. Epub 2018 Nov 28.
The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes (MIR-34b/c, MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs. 4-19%, p<0.001). Using ROC-analysis, we selected an effective system of 4 markers for diagnosis of ovarian cancer (MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) characterized by high sensitivity and specificity (up to 87-94% at AUC=0.92) relative to the conventional norm (54 paired samples of histologically unchanged tissue) and absolute norm (18 ovarian tissue samples from subjects who died from non-tumor diseases). It was also shown that methylation of MIR-129-2, MIR-9-1, and MIR-34b/c genes is significantly (p<0.01) correlated with the clinical stage or the presence of metastases. The results indicate that epigenetic modifications of the studied microRNA genes are involved in the pathogenesis and progression of ovarian cancer and attest to their diagnostic and prognostic potential.
本研究旨在确定恶性卵巢肿瘤中发生高甲基化的微小RNA基因,筛选该疾病新的诊断和预后标志物以及有效的标志物体系。通过甲基化特异性PCR和54例卵巢癌标本的代表性样本,我们确定了5个微小RNA基因(MIR-34b/c、MIR-9-1、MIR-124-3、MIR-129-2和MIR-107)在大多数肿瘤样本中发生了高甲基化,与配对的组织学未改变的组织样本相比(48 - 57%对4 - 19%,p<0.001)。通过ROC分析,我们筛选出了一个用于诊断卵巢癌的4种标志物的有效体系(MIR-9-1、MIR-124-3、MIR-129-2和MIR-107),相对于传统标准(54例配对的组织学未改变的组织样本)和绝对标准(18例死于非肿瘤疾病受试者的卵巢组织样本),该体系具有高敏感性和特异性(AUC = 0.92时高达87 - 94%)。研究还表明,MIR-129-2、MIR-9-1和MIR-34b/c基因的甲基化与临床分期或转移的存在显著相关(p<0.01)。结果表明,所研究的微小RNA基因的表观遗传修饰参与了卵巢癌的发病机制和进展,并证明了它们的诊断和预后潜力。